Study of KK2430 for Blood Cell Cancers
Part of Blood & lymphatic, Cancer clinical trials.
This is an early-stage study testing a new drug called KK2430 in people with blood cancers (like leukemia or lymphoma). The goal is to find the right dose and see if it helps shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have a blood cancer with tumors that can be measured on a scan (CT or MRI)
- Your overall health is good enough for chemotherapy (ECOG score of 0, 1, or 2)
- You agree to provide a fresh tumor sample at the start of the study
- Your blood counts, kidney, and liver function are within acceptable ranges
- You agree to use effective birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests an experimental medicine (RNK05047) in people with advanced solid tumors or diffuse large B‑cell lymphoma whose standard treatments haven’t worked or can’t be tolerated. It may help shrink tumors and improve control of the disease, but early-phase trials also focus on safety and dosing.
This study tests a new experimental drug, KK2260, for people with advanced or advanced solid tumors, especially esophageal cancer and certain head and neck cancers. The goal is to see if the drug is safe and helps shrink or control the cancer.
This study tests a new drug called KK2223 for people with certain types of T-cell lymphoma (PTCL or CTCL) that have not responded to previous treatments. The goal is to find out if the drug is safe and if it helps shrink or control the lymphoma.
This trial is testing a new drug, KK2845, for people with certain blood cancers that have come back or not responded to treatment. It focuses on acute myeloid leukemia (AML) and other blood cancers.
This study tests a new drug, S243249, for adults with certain types of acute leukemia that have come back or not responded to treatment. The drug targets changes in the leukemia cells, which may help control the disease.
This trial tests a new drug called KH801, which may help the immune system fight cancer. It's for people whose cancer has spread or can't be removed and who have already tried other treatments without success. The goal is to see if the drug is safe and if it helps slow down the cancer.
Hear when a new Hematologic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.